Ex-Valeant, Philidor executives get prison time in multimillion-dollar kickback case

Gavel court room lawsuit judge
A former Valeant executive and ex-Philidor CEO were sentenced to one year in prison for conspiring against Valeant. (Pixabay)

Found guilty of defrauding Valeant in a multimillion-dollar kickback scheme, former company executive Gary Tanner and ex-Philidor CEO Andrew Davenport were both sentenced to a year and a day in prison by a New York judge.

The charges stemmed from a too-cozy relationship between Valeant and Philidor, the specialty pharmacy that distributed some of the company's drugs. Tanner and Davenport were accused of steering Valeant toward a $133 million Philidor takeover and away from using competitor pharmacies—and netting millions in the process.

The sentences came in below the prosecutors’ ask, probably thanks to letters of support from family and friends depicting the defendants as hard workers and devoted family members. The prosecutors had requested “substantially above” the Probation Office’s recommendation of 30 months of imprisonment, while defense attorneys were calling for probation instead of prison time.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The two former executives were also each ordered to give back about $9.7 million, the amount involved in the kickback plan.

RELATED: Former executive's fraud trial dredges up a scandal Valeant would love to forget

Valeant has yet to respond to a FiercePharma request for comment by publication time. In its court filing as a non-party in the case, the company said the pair led it to pay more for the buyout option and agreed to a larger Philidor discount for its drugs, and it also argued that Tanner was overpaid for being a “disloyal employee.” Therefore, it requested the court to order $15.5 million in restitution from the defendants.

The sentences are based on convictions handed to the two former execs in May. A spokesman from WilmerHale, the firm representing Tanner, told FiercePharma that they plan to appeal the conviction. Davenport’s lawyer, Sharon McCarthy also said on Tuesday that she plans to appeal, according to The Wall Street Journal.

Valeant’s questionable relationship with now-defunct specialty pharmacy Philidor has come under extensive scrutiny. Valeant allegedly controlled the pharmacy to promote its own expensive branded drugs against cheap generics. Those Valeant drugs once accounted for at least 90% Philidor's dispensing, prosecutors said.

RELATED: Valeant reveals yet another probe of its Philidor relationship

But in this case, the Canadian pharma was painted as the victim of a fraud scheme dreamed up by Tanner and Davenport. The two “conspired to deceive and defraud Tanner’s employer, Valeant, in order to enrich them both,” said U.S. Attorney Geoffrey Berman in a statement.

According to the charges, Tanner was secretly promoting Philidor’s interest while serving as the Valeant executive responsible for managing the ties between the two companies. He helped Davenport land a $133 million Philidor takeover by Valeant and steered Valeant away from using other potential competitor pharmacies. In exchange, Davenport offered Tanner $9.7 million in kickbacks out of the roughly $50 million he personally received through the deal.

Since the fraudulent marketing scandal came to light in 2015, Valeant cut ties with Philidor—which later closed shop—but couldn’t stop a sharp decline in its share price. Its former CEO J. Michael Pearson stepped down in 2016, giving way to current helmsman Joseph Papa. And more recently, the company rebranded as Bausch Health, hoping to turn the page on its tainted reputation.

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.